ALLOVIR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

February 1, 2024 by Gias ul Hassan

If you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ALVR. There is no cost … Read more

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investor of AlloVir, Inc. – ALVR

December 22, 2023 by Gias ul Hassan

NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether AlloVir and certain of its officers and/or directors have engaged in securities fraud or other unlawful … Read more

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

December 22, 2023 by Gias ul Hassan

Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. … Read more

May 16, 2024